Chronic Hepatitis b, Hepatic Fibrosis, Hepatic Steatosis
Conditions
Keywords
Ultrasound Attenuation Imaging
Brief summary
The investigator aimed to prospectively study the effect of the hepatic fibrosis on quantifying hepatic steatosis using ultrasound attenuation imaging (ATI value) in patients with chronic hepatitis B.
Detailed description
Chronic hepatitis B virus (HBV) infection has been reported to be associated with the prevalence of non-alcoholic fatty liver disease (NAFLD). Prior studies demonstrate that concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. Therefore, quantification of hepatic steatosis and fibrosis in chronic hepatitis B patient has important clinical significance in active surveillance. Ultrasound imaging provides reliable noninvasive quantification of hepatic steatosis and fibrosis. Attenuation imaging (ATI) reflects hepatic steatosis and 2D-shear wave elastography reflects hepatic fibrosis. The potential interaction between of the hepatic fibrosis and the hepatic steatosis in chronic hepatitis B is not fully understood. The investigator investigated the effect of the hepatic fibrosis on quantifying hepatic steatosis using ultrasound attenuation imaging (ATI value) in patients with chronic hepatitis B.
Interventions
None listed
Sponsors
Canon Medical Systems, Korea
So Yeon Kim
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
No
Inclusion criteria
* Chronic hepatitis B patients * Who is scheduled for pathological exam such as liver biopsy or surgery, that can quantify hepatic steatosis and hepatic fibrosis * Who submitted informed consent
Exclusion criteria
* Who underwent liver transplantation or right hemihepatectomy * Huge hepatic mass or numerous cysts in right hepatic lobe, who is not eligible for measuring ultrasound attenuation imaging and Fibroscan * High bleeding risk patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Attenuation Coefficient (AC) value at liver parenchyma | During procedure | decibel(dB)/cm/megahertz(MHz) |
| Pathological hepatic steatosis | During procedure | Non-alcoholic Steatohepatitis(NASH) Clinical Research Network scoring system as follows: S0, \<5%; S1, 5%-33%; S2, 34%-66%; S3, ≥67% |
| Pathological hepatic fibrosis | During procedure | Meta-analysis of histological data in viral hepatitis(METAVIR) scoring system as follows: F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis with rare septa; F3, numerous septa without cirrhosis; and F4, cirrhosis |
Countries
South Korea
Outcome results
None listed